GlassScriptPhysician profile
Cally Rae Lampe
NPI 1205407830
$5,442.64
in general payments reported to CMS, 2019-2025
46 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $1,803 · 2023: $883 · 2024: $1,095 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.60 | 2021-2025 | |
| Eisai INC. | $423.63 | 2021-2025 | |
| Emd Serono, INC. | $329.59 | 2021-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $312.04 | 2022-2025 | |
| Argenx US, INC. | $250.83 | 2022-2025 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $227.95 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $190.73 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $185.18 | 2022 | |
| Genzyme Corporation | $177.93 | 2022-2025 | |
| Ucb, INC. | $176.89 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Ani Pharmaceuticals, INC. | $161.80 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $149.22 | 2022-2025 | Ultomiris |
| Lundbeck LLC | $145.49 | 2022-2025 | Vyepti |
| Biogen, INC. | $139.70 | 2021-2024 | Skyclarys, Vumerity, Tysabri |
| Avion Pharmaceuticals | $136.37 | 2022-2023 | Dhivy |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $123.08 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $112.25 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $106.06 | 2021-2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $102.88 | 2022-2023 | Rytary |
| Tanabe Pharma America, INC. | $73.19 | 2022-2024 | |
| Amgen INC. | $56.73 | 2021-2022 | |
| Livanova USA, INC. | $51.86 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $51.48 | 2021-2023 | Acthar |
| Neurelis, INC. | $48.50 | 2021-2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $48.46 | 2021-2024 | Austedo Xr |
| Mdd US Operations, LLC | $46.60 | 2022-2025 | Gocovri |
| Amylyx Pharmaceuticals, INC. | $45.99 | 2023 | Relyvrio |
| Kyowa Kirin, INC. | $44.37 | 2022-2023 | Nourianz |
| Acorda Therapeutics, INC | $43.97 | 2023 | Inbrija |
| Csl Behring | $35.52 | 2021-2022 | |
| Axsome Therapeutics, INC. | $35.23 | 2024-2025 | Sunosi |
| Chiesi USA, INC. | $32.92 | 2021 | |
| Xeris Pharmaceuticals, INC. | $31.49 | 2023 | Gvoke Hypopen, Keveyis |
| Impel Pharmaceuticals INC. | $31.41 | 2022-2023 | Trudhesa |
| Allergan, INC. | $29.27 | 2021-2022 | |
| Horizon Therapeutics Plc | $24.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.65 | 2023 | Ponvory |
| Corium, LLC | $22.91 | 2023 | Adlarity, Adlarity |
| Sunovion Pharmaceuticals INC. | $21.35 | 2022 | |
| Tg Therapeutics, INC. | $20.70 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.62 | 2025 | Rexulti |
| Boston Scientific Corporation | $14.64 | 2023 | Watchman Access System |
| Grifols USA, LLC | $14.21 | 2023 | Gamunex-C |
| Biohaven Pharmaceuticals, INC. | $13.41 | 2021 | |
| Banner Life Sciences, LLC | $12.72 | 2022 | |
| Amicus Therapeutics, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cally Lampe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.